SUPPLEMENTAL DIGITAL CONTENT

Table S1. Virologic outcomes for all patients not responding to therapy (plasma HIV-1 RNA >50 copies/mL) at Week 48

	Plasma HIV-1 RNA, copies/mL		
	Baseline	**Week 48**	**Post-Week 48**
MVC + ATV/r			
A[a] (10181003)	2.2×10^5	69	497 (Week 84)
B (10281004)	3.0×10^4	144	<50 (Week 96)
C (10611005)	3.5×10^4	57	<50 (Week 72)
D (10641001)	2.8×10^5	81	<50 (Week 84)
E (10641006)	3.9×10^4	167	<50 (Week 96)
F[b] (10671002)	1.7×10^4	87	274 (Week 96)
G (10761008)	1.2×10^5	61	<50 (Week 72)
H (10801005)	1.2×10^5	51	<50 (Week 84)
I (10801010)	6.0×10^4	58	<50 (Week 84)
TDF/FTC + ATV/r			
J (10231003)	2.6×10^5	52	<50 (Week 84)
K (10501004)	3.4×10^4	780	<50 (Week 96)
L (10641002)	1.3×10^5	55	<50 (Week 84)

[a]Patient discontinued at Week 84 due to insufficient clinical response

[b]Patient discontinued at Week 96

ATV/r, atazanavir/ritonavir; MVC, maraviroc; TDF/FTC, tenofovir/emtricitabine

SUPPLEMENTAL DIGITAL CONTENT



ATV/r, atazanavir/ritonavir; MVC, maraviroc; TDF/FTC, tenofovir/emtricitabine

Figure S1. Proportion of patients with HIV-1 RNA <400 copies/mL by study visit

SUPPLEMENTAL DIGITAL CONTENT

Table S2. Summary of treatment-emergent adverse events occurring in ≥10% of patients in either treatment group, and incidence of Grade-3/4 laboratory test abnormalities, among all patients who received ≥1 dose of study medication.

	Treatment group, n (%) patients			
	MVC + ATV/r (n=60)		**TDF/FTC + ATV/r (n=61)**	
Treatment-emergent adverse events				
Adverse event potentially associated with hyperbilirubinemia	46 (76.7)		33 (54.1)	
Diarrhea	13 (21.7)		14 (23.0)	
Upper respiratory tract infection	7 (11.7)		7 (11.5)	
Vomiting	6 (10.0)		5 (8.2)	
Bronchitis	6 (10.0)		4 (6.6)	
Headache	5 (8.3)		7 (11.5)	
Nausea	4 (6.7)		14 (23.0)	
Grade-3/4 laboratory test abnormalities (DAIDS)				
	n=59		n=61	
	Grade 3	Grade 4	Grade 3	Grade 4
Hyperbilirubinemia	30 (50.8)	9 (15.3)	29 (47.5)	3 (4.9)

SUPPLEMENTAL DIGITAL CONTENT

Alanine aminotransferase	3 (5.1)	0	0	1 (1.6)
Aspartate aminotransferase	2 (3.4)	0	1 (1.6)	1 (1.6)
Serum amylase	2 (3.4)	0	2 (3.3)	0
Absolute neutrophil count	1 (1.7)	0	1 (1.6)	0
Potassium (hyperkalemia)	0	0	0	1 (1.6)

Grade 3=severe; Grade 4=very severe

ATV/r, atazanavir/ritonavir; DAIDS, Division of AIDS (Table for Grading the Severity of Adult and Pediatric Adverse Events); MVC, maraviroc; TDF/FTC, tenofovir/emtricitabine



ATV/r, atazanavir/ritonavir; MVC, maraviroc; TDF/FTC, tenofovir/emtricitabine

SUPPLEMENTAL DIGITAL CONTENT

Figure S2. Change from baseline in creatinine clearance calculated using the Cockcroft-Gault formula